<DOC>
	<DOCNO>NCT01395628</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood tissue patient cancer laboratory may help doctor learn cancer development drug resistance patient . It may also help doctor find good way treat cancer . PURPOSE : This research trial study sample patient leukemia .</brief_summary>
	<brief_title>Cell Samples From Patients With Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Demonstrate capability primary human leukemia sample survive proliferate zebrafish embryo . - Confirm anti-proliferative toxic effect know chemotherapeutics transplant cell vivo . - Evaluate effect novel anticancer drug and/or combination individual sample . OUTLINE : This multicenter study . Cryopreserved specimens inject yolk sac zebrafish embryo anesthesia . After 1 hour recovery 28° C , embryo maintain 38° C screen fluorescence injection site . Within 48 hour post-injection , embryos treat various chemotherapeutic drug dimethyl sulfoxide incubated protease solution . Proliferation leukemia cell monitor live-cell microscopy . Cells without drug treatment extract 24 72 hour post-injection . Leukemia cell count test imatinib mesylate , all-trans retinoic acid ( tretinoin ) , cytosine arabinose , know bioactive chemical compound promise drug family , tyrosine kinase inhibitor , antiapoptotic agent , channel modulators , prostaglandin agonist .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Samples blood tissue cell patient diagnose myeloid disease include follow subtypes : Chronic phase chronic myeloid leukemia ( CML ) , complement initial study K562 CML cell line Acute promyelocytic leukemia ( APL ) , complement initial study NB4 APL cell line Acute myeloid leukemia ( AML ) express ( 8 ; 21 ) ( q22 ; q22 ) translocation , occur approximately 12 % pediatric AML associate good prognosis AML express 5q monosomy 7 , associate poor prognosis AML express fmslike tyrosine kinase 3 internal tandem duplication ( FLT3ITD ) , associate poor prognosis PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>childhood acute myeloid leukemia/other myeloid malignancy</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia del ( 5q )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
</DOC>